GlobalData on MSN2d
Abcuro secures $200m as it eyes approval for rare muscle disease drug
The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
BioSpace2d
Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...
pharmaphorum2d
Abcuro raises $200m to take muscle disease drug to market
US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...